Mazdutide

• Mazdutide (IBI362 / LY3305677) is a dual GLP-1 + glucagon receptor agonist — an oxyntomodulin analog. It's a different dual-agonist than tirzepatide (which is GLP-1/GIP): mazdutide pairs GLP-1 appetite suppression with glucagon-driven thermogenesis and hepatic fat metabolism.
• ⚠️ Verify before relying on the numbers: the headline Phase 3 results (GLORY/DREAMS program — e.g. ~20% weight loss at 9 mg over 60 weeks) are company/topline-stage, 2025-dated, and from largely Chinese cohorts. Treat them as unverified until confirmed against the primary publications.
• Mechanistically it fills the GLP-1/glucagon slot in the incretin landscape (semaglutide = GLP-1; tirzepatide = GLP-1/GIP; retatrutide = triple agonist; survodutide = also GLP-1/glucagon).
• It is not FDA-approved and is developed by Innovent/Lilly, with most trials run in Chinese populations.

Mazdutide is an investigational once-weekly injectable for obesity and type 2 diabetes built on oxyntomodulin — a gut hormone that naturally activates both GLP-1 and glucagon receptors. The dual mechanism is the pitch: GLP-1 cuts appetite while glucagon raises energy expenditure and mobilizes liver fat, with the GLP-1 arm offsetting glucagon's tendency to raise blood sugar.

It is not FDA-approved, and several of the figures below are company-reported/topline — flagged where that's the case. Everything here is research context, not medical guidance.

Mazdutide is a ~4,563 Da, 33-amino-acid oxyntomodulin analog. Like the long-acting incretin drugs, it carries a C20 fatty-diacid chain (conjugated via a hydrophilic linker at Lys20) that binds albumin and extends its half-life enough for once-weekly dosing — the same strategy used by semaglutide. A missed dose can reportedly be taken within ~3 days.

Its defining feature is the receptor pair: GLP-1 + glucagon. That makes it the dual-agonist sibling of survodutide, and a contrast to tirzepatide's GLP-1/GIP pairing.

There is no approved dosing. The figures below are the once-weekly, 4-week-step escalation schedules used in trials, included for research context only.

• Toward 3 mg: 1.5 → 3 mg; toward 4.5 mg: 1.5 → 3 → 4.5 mg
• Toward 6 mg: 2 → 4 → 6 mg; toward 9 mg (max weight loss): 3 → 6 → 9 mg
• T2D (mild-moderate): ~3–4.5 mg/week; T2D + obesity (intensive): ~6–9 mg/week
• Any time of day, with or without food, on a consistent weekly day

• GLORY-2 (Phase 3, 9 mg, 60 wk): reported ~20.1% mean weight loss vs ~2.8% placebo, with ~48.7% of non-diabetics losing ≥20% and no plateau through 60 weeks — company/topline, pending verification.
• GLORY-1 (Phase 3, 48 wk, 4/6 mg): reported significant weight loss vs placebo; an exploratory liver-fat reduction signal (MASLD/MASH interest).
• DREAMS-3 (head-to-head vs semaglutide, T2D + obesity, 32 wk): reported more patients hitting combined HbA1c <7% AND ≥10% weight loss — company/topline.
• Metabolic markers reported to improve (waist, blood pressure, triglycerides).

All GLORY/DREAMS figures here are company-reported/topline and 2025-dated from largely Chinese cohorts. Confirm against the primary peer-reviewed publications before citing as established.

The profile is typical of incretin drugs: dose-dependent gastrointestinal effects (nausea, diarrhea, vomiting), mostly mild-to-moderate and managed by the 4-week step escalation. A heart-rate increase (~5–17 bpm) was reported without cardiac events in trials. Standard GLP-1-class cautions carry over: monitor for pancreatitis; contraindicated with a personal/family history of medullary thyroid carcinoma or MEN 2; reduce insulin/sulfonylurea doses to avoid hypoglycemia; not for use in pregnancy/breastfeeding. Other incretin agonists (semaglutide, tirzepatide, liraglutide) should not be combined with it.

• Reconstitute with bacteriostatic water added slowly down the vial wall (drop-by-drop to avoid foaming); swirl gently, never shake; solution should be clear and colorless.
• Lyophilized: −20°C long-term. Reconstituted: 2–8°C, use within ~30 days; avoid freeze-thaw.
• Research-chemical supply — source verification matters; reject clumping, discoloration, moisture, or persistent cloudiness.

Mazdutide is investigational and not FDA-approved. It is developed by Innovent/Eli Lilly (trials largely in Chinese populations) and is sold by research-chemical suppliers for laboratory use only, not intended for human consumption.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.